These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16241986)

  • 1. Hass J, Firzlaff M (2005). Twenty-four-month comparison of immunomodulatory treatments--a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology 12:425-431.
    Hasford J
    Eur J Neurol; 2005 Nov; 12(11):916-7; author reply 917. PubMed ID: 16241986
    [No Abstract]   [Full Text] [Related]  

  • 2. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).
    Haas J; Firzlaff M
    Eur J Neurol; 2005 Jun; 12(6):425-31. PubMed ID: 15885045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
    Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
    Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunomodulatory treatments for multiple sclerosis.
    Durelli L; Clerico M
    Eur J Neurol; 2005 Nov; 12(11):915; author reply 916. PubMed ID: 16241984
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glatiramer acetate for multiple sclerosis.
    Drug Ther Bull; 2001 Jun; 39(6):41-3. PubMed ID: 11432030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Emerging new therapies for relapsing remitting multiple sclerosis].
    Anis S; Achiron A
    Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain].
    Sánchez-De la Rosa R; Sabater E; Casado MA
    Rev Neurol; 2011 Aug; 53(3):129-38. PubMed ID: 21748710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis.
    Qizilbash N; Mendez I; Sanchez-de la Rosa R
    Clin Ther; 2012 Jan; 34(1):159-176.e5. PubMed ID: 22284996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.
    Yildiz M; Tettenborn B; Putzki N
    Eur Neurol; 2011; 65(4):231-2. PubMed ID: 21454981
    [No Abstract]   [Full Text] [Related]  

  • 13. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).
    Balabanov R; Lisak D; Beaumont T; Lisak RP; Dore-Duffy P
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1196-203. PubMed ID: 11687463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
    Darbà J; Kaskens L; Sánchez-de la Rosa R
    J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do interferon beta-1b and glatiramer acetate grow brain?
    Rudick RA; Fisher E
    Lancet Neurol; 2009 Dec; 8(12):1085-6; author reply 1086-7. PubMed ID: 19909906
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain].
    Rubio-Terrés C; Arístegui Ruiz I; Medina Redondo F; Izquierdo Ayuso G
    Farm Hosp; 2003; 27(3):159-65. PubMed ID: 12835817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
    J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.
    Mäurer M; Dachsel R; Domke S; Ries S; Reifschneider G; Friedrich A; Knorn P; Landefeld H; Niemczyk G; Schicklmaier P; Wernsdörfer C; Windhagen S; Albrecht H; Schwab S;
    Eur J Neurol; 2011 Aug; 18(8):1036-45. PubMed ID: 21199183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness of glatiramer acetate in clinical practice conditions.
    Arnal-García C; Amigo-Jorrin Mdel C; López-Real AM; Lema-Devesa C; Llopis N; Sanchez-de la Rosa R;
    J Clin Neurosci; 2014 Dec; 21(12):2212-8. PubMed ID: 25257663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.